Dosimetric Analysis of Lu-177-cG250 Radioimmunotherapy in Renal Cell Carcinoma Patients: Correlation with Myelotoxicity and Pretherapeutic Absorbed Dose Predictions Based on In-111-cG250 Imaging

Alexander B. Stillebroer, Catharina M. Zegers, Otto C. Boerman*, Egbert Oosterwijk, Peter F. A. Mulders, Joseph A. O'Donoghue, Eric P. Visser, Wim J. G. Oyen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Abstract
This study aimed to estimate the radiation absorbed doses to normal tissues and tumor lesions during radioimmunotherapy with (177)Lu-cG250. Serial planar scintigrams after injection of (111)In-cG250 or (177)Lu-cG250 in patients with metastasized renal cell carcinoma were analyzed quantitatively. The estimated radiation doses were correlated with observed hematologic toxicity. In addition, the accuracy of the predicted therapeutic absorbed doses, based on diagnostic (111)In-cG250 data, were determined.

METHODS:
Twenty patients received a diagnostic tracer activity of (111)In-cG250 (185 MBq), followed by radioimmunotherapy with (177)Lu-cG250. The administered activity of (177)Lu-cG250 was escalated by entering 3 patients at each activity level starting at 1,110 MBq/m(2), with increments of 370 MBq/m(2). After each diagnostic and therapeutic administration, whole-body scintigraphic images and pharmacokinetic data were acquired. Hematologic toxicity was graded using the Common Toxicity Criteria, version 3.0. Diagnostic (111)In-cG250 data were used to simulate (177)Lu and (90)Y data by correcting for the difference in physical decay. Absorbed doses were calculated for the whole body, red marrow, organs, and tumor metastases for the therapeutic (177)Lu-cG250, simulated (177)Lu-cG250, and simulated (90)Y-cG250 data.

RESULTS:
Observed hematologic toxicity, especially platelet toxicity, correlated significantly with the administered activity (r = 0.85), whole-body absorbed dose (r = 0.65), and red marrow dose (r = 0.62 and 0.75). An inverse relationship between the mass and absorbed dose of the tumor lesions was observed. Calculated mean absorbed doses were similar for the simulated and measured (177)Lu-cG250 data. Absorbed doses (whole body and red marrow) based on the simulated (177)Lu-cG250 data correlated with the observed platelet toxicity (r = 0.65 and 0.82). The tumor-to-red marrow dose ratio was higher for radioimmunotherapy with (177)Lu-cG250 than for radioimmunotherapy with (90)Y-cG250, indicating that (177)Lu has a wider therapeutic window for radioimmunotherapy with cG250 than (90)Y.

CONCLUSION:
In patients with metastasized renal cell carcinoma, hematologic toxicity after treatment with (177)Lu-cG250 can be predicted on the basis of administered activity and whole-body and red marrow-absorbed dose. Diagnostic (111)In-cG250 data can be used to accurately predict absorbed doses and myelotoxicity of radioimmunotherapy with (177)Lu-cG250. These estimations indicate that in these patients, higher radiation doses can be guided to the tumors with (177)Lu-cG250 than with (90)Y-cG250.
Original languageEnglish
Pages (from-to)82-89
Number of pages8
JournalJournal of Nuclear Medicine
Volume53
Issue number1
DOIs
Publication statusPublished - Jan 2012
Externally publishedYes

Keywords

  • radioimmunotherapy
  • cG250
  • predictive dosimetry
  • myelotoxicity
  • MONOCLONAL-ANTIBODY G250
  • NON-HODGKINS-LYMPHOMA
  • BODY-SURFACE AREA
  • RADIATION-DOSIMETRY
  • HEMATOLOGIC TOXICITY
  • RADIONUCLIDE THERAPY
  • NUCLEAR-MEDICINE
  • CANCER
  • ANTIGEN
  • BIODISTRIBUTION

Cite this